Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
A large study has shown that screening programmes among people at risk of lung cancer could save lives.
The NELSON trial was carried out in the Netherlands and Belgium and involved 15,792 people who were at a high risk of developing lung cancer.
Participants were split into two groups at random – one group was offered screening and one group was not. The screening involved regular computerised tomography (CT) scans (where a person’s body is X-rayed at several angles before a computer puts together a detailed image). This could help to detect lung cancer at an earlier stage – when it is can be treated more easily.
As part of the study, each person was followed up for at least 10 years, to see if there was a difference in survival rates between those offered screening and those who were not. Overall, the researchers found that screening improved survival rates – with a 26% reduction in lung cancer deaths among men.
This trial could mark a potential turning point for lung cancer care. The European Respiratory Society (ERS) has welcomed these long-awaited results. ERS is encouraging countries in Europe to establish lung cancer screening programmes for people at high risk as soon as possible, and is calling upon the EU to produce guidelines to support its member states in doing so.
Read the full press release on the NELSON trial.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79